Rot I, Wassersug RJ, Walker LM. 2016. What do urologists think patients need to know when starting on androgen deprivation therapy? The perspective from Canada versus countries with lower gross domestic product. Transl Androl Urol 5:235-247.

Wassersug RJ. 2016. Maintaining intimacy for prostate cancer patients on androgen deprivation therapy. Curr Opin Support Palliat Care 10:55-65.



Lee TK, Handy AB, Kwan W, Oliffe JL, Brotto LA, Wassersug RJ, Dowsett GW. 2015. Impact of prostate cancer treatment on the sexual quality of life for men-who-have-sex-with-men. J Sex Med 12:2378-86.

Hamilton LD, Van Dam D, Wassersug RJ. 2015. The perspective of prostate cancer patients and patients' partners on the psychological burden of androgen deprivation and the dyadic adjustment of prostate cancer couples. Psychooncology 25:823-31.

Donovan KA, Walker LM, Wassersug RJ, Thompson LM, Robinson JW. 2015. Psychological effects of androgen-deprivation therapy on men with prostate cancer and their partners. Cancer 121:4286-99. 

Van Dam D, Wassersug RJ, Hamilton LD. 2015. Androgen deprivation therapy’s impact on the mood of prostate cancer patients as perceived by patients and the partners of patients. Psycho-Oncology 25:848-56.

Walker LM, Wassersug RJ, Robinson JW. 2015. Psychosocial perspectives on sexual recovery after prostate cancer treatment. Nat Rev Urol 12:167-176. 



McLeod DL, Walker LM, Wassersug RJ, Matthew A, Robinson JW. 2014. The sexual and other supportive care needs of Canadian prostate cancer patients and their partners: Defining the problem and developing interventions. Canadian Oncology Nursing Journal 24:272-278.

Tran S, Walker LM, Wassersug RW, Matthew AG, McLeod DL, Robinson JW. 2014. What do Canadian uro-oncologists believe patients should know about androgen deprivation therapy? J Oncol Pharm Pract. 20:199-209.



Walker LM, Tran S, Wassersug RJ, Thomas B, Robinson JW. 2013. Patients and partners lack knowledge of androgen deprivation therapy side effects. Urol Oncol 31:1098-1105.

Walker LM, Tran S, Robinson JW. 2013. Luteinizing hormone—releasing hormone agonists: a quick reference for prevalence rates of potential adverse effects. Clin Genitourin Cancer. 11:375-384.

Kukula KC, Jackowich RA, Wassersug RW. 2013. Eroticization as a factor influencing ED treatment effectiveness. Inter J Impotence Res. 26:1-6.

Wassersug RJ. 2013. Extending the case for oestradiol in androgen-sensitive prostate cancer. Lancet Oncol. 14:e242-3.

Walker LM, Hampton AJ, Wassersug RJ, Thomas BC, Robinson RJ. 2013. Androgen deprivation therapy and maintenance of intimacy: A randomized controlled pilot study of an educational intervention for patients and their partners. Contemp Clinical Trials 34:227-231.



Wibowo E, Deurveilher S, Wassersug RJ, Semba K. 2012. Estradiol treatment modulates spontaneous sleep and sleep recovery after sleep deprivation in castrated male rats. Behav Brain Res. 226:456-464.

Walker L, Tran S, Wassersug RJ, Thomas B, Robinson J. 2012. Patients and partners lack knowledge of androgen deprivation therapy side effects. Urol Oncol. 31:1098-105.

Rot I, Ogah I, Wassersug RJ. 2012. The language of prostate cancer treatments and implications for informed decision making by patients and their partners. Eur J Cancer Care. 21:766-775.

Wibowo E, Wassersug R, Warkentin K, Walker L, Robinson J, Brotto L, Johnson T. 2012. Impact of androgen deprivation therapy on sexual function: A response. Asian J Androl. 14:793-794.

Phillips JL, Wassersug RJ, McLeod D. 2012. Systemic bias in the medical literature on androgen deprivation therapy and its implication to clinical practice. Int J Clin Practice. 66:1189-1196.

Ogah I, Wassersug RJ. 2012. How reliable are "reputable sources" for medical information on the internet?—The case of hormonal therapy to treat prostate cancer. Urol Oncol. 31:1546-1552.

Aning JJ, RJ Wassersug RJ, Goldenberg LS. 2012. Patient preferences and the impact of decision-making aids on prostate cancer treatment choices and post-intervention regret. Current Oncol. 19:S37-S44.



Murphy R, Wassersug RJ, Dechman G. 2011. The role of exercise in managing the adverse effects of androgen deprivation therapy in men with prostate cancer. Phys Therapy Rev. 16:269-277.

Wibowo E, Schellhammer P, Wassersug RJ. 2011. Role of estrogen in normal male function: Clinical implications for patients with prostate cancer on androgen deprivation therapy. J Urol, 185:17-23.



Elliott S, Latini DM, Walker LM, Wassersug RJ, Robinson JW. 2010. Androgen deprivation therapy for prostate cancer: Recommendations to improve patient and partner quality of life. J Sex Med. 7: 2996–3010.



Wassersug RJ. 2009. Mastering emasculation. J Clin Oncol. 27:634-636.